Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1771 • ACR Convergence 2022
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Yanjie Hao¹, Shereen Oon² and Mandana Nikpour³, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
Abstract Number: 1960 • ACR Convergence 2022
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
Theresa Than¹, Emmanuelle Dernis², Olivier BROCQ³, Bruno Fautrel⁴, Helena HUGUET⁵, Liana Euller-Ziegler⁶, Lindsay BUSTAMENTE-CENCI⁶, Olivier Vittecoq⁷, Marie-christine PICOT⁵, Cédric Lukas⁸, Claire DAIEN⁹, Charlotte Hua¹⁰, Marlène Genty⁵, Helene Che⁵, Anouck REMY-MOULARD¹¹, Frederic LIOTE¹², Martin Soubrier¹³, Cécile GAUJOUX-VIALA¹⁴, Arnaud Constantin¹⁵, Alain Saraux¹⁶, Emilie Ducourau¹⁷, Stephanie RIST¹⁸, CARINE SALLIOT¹⁹, Nada IBRAHIM-NASSER¹⁸, Clara qUINTEN¹⁸, Vincent Goeb²⁰ and Jacques Morel¹, ¹University and CHU Montpellier, Montpellier, France, ²LE MANS general hospital, LE MANS, France, ³Centre hospitalier Princesse-Grace, Monaco, France, ⁴Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁵CHU Montpellier, Montpellier, France, ⁶CHRU Nice, Nice, France, ⁷CHU de Rouen, ROUEN, France, ⁸University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ⁹University Hospital, Saint-Gély-du-Fesc, France, ¹⁰La Lettre du Rhumatologue, Paris, France, ¹¹CHU Montpellier, Montpellier, Chad, ¹²University of Paris, Paris, France, ¹³Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁴CHU Nîmes, Univ Montpellier (IDESP), Nîmes, France, ¹⁵Toulouse University Hospital, Toulouse, France, ¹⁶CHU Brest, Brest, France, ¹⁷CH Orleans, Chambray Les Tours, France, ¹⁸CH orleans, Orleans, France, ¹⁹CHR orleans, Orleans, France, ²⁰CHU Amiens, Amiens, France
Background/Purpose: It is recommended that vaccinations should be performed prior to start methotrexate (MTX) knowing that delaying initiation of background therapy may have an impact…
Abstract Number: 1978 • ACR Convergence 2022
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Alexandra Legge¹ and Diane Lacaille², ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
Abstract Number: 1995 • ACR Convergence 2022
Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
Stephan Kemenes¹, Koray Tascilar², David Simon¹, Sara Bayat³, Gerhard Kroenke², Larissa Valor Mendez², Fabian Hartmann⁴, Louis Schuster⁴, Anna-Maria Liphardt¹, Georg Schett⁵ and Arnd Kleyer², ¹Department of Internal Medicine 3, Rheumatoloy and Immunology, University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁴University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Deterioration of peripheral bone mass and bone biomechanics are well-known consequences of Rheumatoid Arthritis (RA)[1]. CCP-AB pos. RA, in particular, leads to a significant…
Abstract Number: 2011 • ACR Convergence 2022
More Meticulously Following Treat-to-target in RA Does Not Lead to Less Radiographic Progression: A Longitudinal Analysis in BIODAM
Sofia Ramiro¹, Robert Landewé², Désirée van der Heijde³, Alexandre Sepriano⁴, Oliver FitzGerald⁵, Mikkel Østergaard⁶, Joanne Homik⁷, Ori Elkayam⁸, Carter Thorne⁹, Maggie Larche¹⁰, Gianfranco Ferraccioli¹¹, Marina Backhaus¹², Gilles Boire¹³, Bernard Combe¹⁴, Thierry Schaeverbeke¹⁵, Alain Saraux¹⁶, Maxime Dougados¹⁷, Maurizio Rossini¹⁸, Marcello Govoni¹⁹, Luigi Sinigaglia²⁰, Alain Cantagrel²¹, CF Allaart¹, Cheryl Barnabe²², Clifton O. Bingham III²³, Dirkjan van Schaardenburg²⁴, HIlde Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter P Maksymowych²⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Leiden University Medical Centre, Portela Loures, Portugal, ⁵Conway Institute, University College Dublin, Dublin, Ireland, ⁶Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁷Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Catholic University of the Sacred Heart, Rome, Roma, Italy, ¹²Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, ¹³Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴CHU Montpellier and Montpellier University, Monpellier, France, ¹⁵FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, Bordeaux, France, ¹⁶CHU Brest, Brest, France, ¹⁷Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ¹⁸Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ¹⁹S. Anna Hospital and University of Ferrara, Ferrara, Italy, ²⁰Gaetano Pini Institute, Milano, Italy, ²¹CHU Toulouse, Paul Sabatier University, Toulouse, France, ²²University of Calgary, Calgary, AB, Canada, ²³Johns Hopkins University, Baltimore, MD, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Diakonhjemmet Hospital, Oslo, Oslo, Norway, ²⁶CARE Arthritis LTD, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have…
Abstract Number: 2205 • ACR Convergence 2022
Non-Invasive in Vivo Metabolic Profiling of Inflammation in Joints and Entheses by Optoacoustic Imaging
Koray Tascilar¹, Filippo Fagni², Arnd Kleyer¹, Sara Bayat², Robert Heidemann³, Florian Steiger³, Gerhard Kroenke¹, Daniela Bohr⁴, Andreas Ramming¹, Melek Yalcin Mutlu³, Ioanna Minopoulou³, Fabian Hartmann³, Daniel Klett⁵, Anna Federle⁵, Adrian Regensburger⁶, Alexandra L. Wagner⁶, Ferdinand Knieling⁶, Markus Neurath⁵, Georg Schett⁷, Maximilian Waldner⁵ and David Simon¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁴Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ⁵University Hospital Erlangen; Department of Internal Medicine 1 - Gastroenterology, Pulmonology and Immunology, Erlangen, Germany, ⁶University Hospital Erlangen; Department of Pediatrics and Adolescent Medicine, Erlangen, Germany, ⁷Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: For individuals with inflammatory arthritis, a detailed metabolic characterization of joints and entheses at the tissue level can aid in early diagnosis and treatment…
Abstract Number: PP06 • ACR Convergence 2022
Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
Lawrence Phillips, Noblesville, IN
Background/Purpose: I was diagnosed with rheumatoid arthritis (RA) in 1999. In 2015 and 2019, two surgeons independently diagnosed me with ankylosing spondylitis (AS) following two…
Abstract Number: 0009 • ACR Convergence 2022
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
Xiaodong Wang, Mark Matijevic, Allen Poma, Shauna Quinn, Minggeng Gao, Lisa Crockett, Jessica Karnes, Keith Wilcoxen and Hua Mu, Zenas BioPharma, Waltham
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across…
Abstract Number: 0076 • ACR Convergence 2022
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
Ko-Jen Li¹, Kuo-Cherh Huang², Chia-Cheng Lin³ and Chia-Li Chang², ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Chugai Pharma Taiwan Ltd., Taipei, Taiwan
Background/Purpose: There is a growing concern over the rise of polypharmacy, arguably one of the most pressing prescribing challenges. The option of biologic monotherapy is…
Abstract Number: 0187 • ACR Convergence 2022
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Herbert Kellner³, Rafaela Ortega-Castro⁴, Julio Cesar Vázquez Perez-Coleman⁵, Foti Rosario⁶, Sławomir Jeka⁷, Boulos Haraoui⁸, Yannick Allanore⁹, Masiur Rahman¹⁰, Fabricio Furlan¹⁰, Sohaib Hachaichi¹¹ and Tom Sheeran¹², ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, England, United Kingdom, ²University Hospital Wuerzburg, Wuerzburg, Germany, ³Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁵University Hospital Complex of Ferrol, A Coruña, Spain, ⁶Policlinico G. Rodolico-S.Marco Hospital, Catania, Italy, ⁷University Hospital No 2 in Bydgoszcz Collegium Medicum UMK, Clinic and Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁸Institut de rhumatologie de Montréal, Montréal, QC, Canada, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Sandoz Hexal AG, Holzkirchen, Germany, ¹¹Hexal AG (A Sandoz company), Holzkirchen, Germany, ¹²New Cross and Cannock Chase Hospitals, University of Wolverhampton, Cannock, United Kingdom
Background/Purpose: COMPACT is a non-interventional study evaluating the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis or psoriatic arthritis…
Abstract Number: 0248 • ACR Convergence 2022
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
Veronica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo¹, Víctor M. Mora-Cuesta¹, David Iturbe-Fernández¹, Leticia Lera-Gómez¹, Diana Prieto-Peña¹, Virgi Portilla¹, Ricardo Blanco², Alfonso Corrales¹, Oreste Gualillo³, José M. Cifrián¹, Raquel Lopez Mejias⁴ and Miguel Ángel González-Gay⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁴IDIVAL, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
Abstract Number: 0264 • ACR Convergence 2022
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Kent Kwas Huston¹, Christopher Adams², Simon Helfgott³, Jasvinder singh⁴, Nehad Soloman⁵, Dan Persons⁶, Scott Milligan⁶ and Colin Edgerton², ¹Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ²Articularis Healthcare, Sullivans Island, SC, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Trio Health, Louisville, CO
Background/Purpose: The development, exacerbation, or unimprovement of clinical conditions during DMARD treatment may lead patients to abandon treatment before the necessary time has elapsed for…
Abstract Number: 0281 • ACR Convergence 2022
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
Maya Buch¹, BERNARD COMBE², Jose A Gomez-Puerta³, Roberto Felice Caporali⁴, jacques-eric gottenberg⁵, Paul Van Hoek⁶, Vijay Rajendran⁷, Pieter-Jan Stiers⁶, Katrien Van Beneden⁶, Daniel Aletaha⁸, Gerd Burmester⁹, Rene Westhovens¹⁰ and Yoshiya Tanaka¹¹, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Montpellier University, Montpellier, France, ³Hospital Clínic de Barcelona, Barcelona, Spain, ⁴University of Milan, Milano, Italy, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos NV, Gent, Belgium, ⁸Medical University Vienna, Wien, Austria, ⁹Charité University Medicine Berlin, Berlin, Germany, ¹⁰University Hospitals Leuven, Leuven, Belgium, ¹¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for the treatment of moderate to severe active RA.1 It was previously reported that…
Abstract Number: 0298 • ACR Convergence 2022
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
Derek Haaland¹, Jonathan Chan², Larissa Lisnevskaia³, Andrew Chow⁴, Tanya Girard⁵, Pierre-André Fournier⁵ and Louis Bessette⁶, ¹The Waterside Clinic, Oro Medonte, ON, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Oshawa Clinic, Oshawa, ON, Canada, ⁴Credit Valley Rheumatology, University of Toronto, Mississauga, ON, Canada, ⁵AbbVie, Saint-Laurent, QC, Canada, ⁶Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada
Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)- inhibitor that has been shown to be effective and well-tolerated in patients with rheumatoid arthritis…
Abstract Number: 0316 • ACR Convergence 2022
Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) – a Novel Treatment Approach for Rheumatoid Arthritis
Christine Landlinger¹, Maroua Ferhat¹, ferdinando Nicoletti² and Michael Thiele¹, ¹OncoOne R&D, Vienna, Austria, ²University of Catania, Catania, Italy
Background/Purpose: Macrophage migration inhibitory factor (MIF) is a primary mediator of adaptive and innate immune responses, as well as a primary counter-regulator of glucocorticoids (GCs),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.